Literature DB >> 11122862

Quality-of-life assessment in advanced cancer.

S Donnelly1.   

Abstract

In the past 5 years, quality-of-life (QOL) assessment measures such as the McGill, McMaster, Global Visual Analogue Scale, Assessment of QOL at the End of Life, Life Evaluation Questionnaire, and Hospice QOL Index have been devised specifically for patients with advanced cancer. The developers of these instruments have tried to respond to the changing needs of this specific population, taking into account characteristics including poor performance status, difficulty with longitudinal study, rapidly deteriorating physical condition, and change in relevant issues. Emphasis has been placed on patient report, ease and speed of completion, and the existential domain or meaning of life. Novel techniques in QOL measurement have also been adapted for palliative care, such as judgment analysis in the Schedule for the Evaluation of Individual Quality of Life. It is generally agreed that a single tool will not cover all QOL assessment needs.

Entities:  

Mesh:

Year:  2000        PMID: 11122862     DOI: 10.1007/s11912-000-0027-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  27 in total

1.  Assessment of quality of life in palliative care--psychometric properties of a short questionnaire.

Authors:  B Axelsson; P O Sjödén
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

2.  Quality of life assessment in advanced cancer.

Authors:  S Donnelly; D Walsh
Journal:  Palliat Med       Date:  1996-10       Impact factor: 4.762

3.  Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain.

Authors:  S R Cohen; B M Mount; E Bruera; M Provost; J Rowe; K Tong
Journal:  Palliat Med       Date:  1997-01       Impact factor: 4.762

4.  The quality of life of patients with cancer receiving hospice care.

Authors:  S C McMillan
Journal:  Oncol Nurs Forum       Date:  1996-09       Impact factor: 2.172

5.  "Clinical Judgment" revisited: the distraction of quantitative models.

Authors:  A R Feinstein
Journal:  Ann Intern Med       Date:  1994-05-01       Impact factor: 25.391

6.  Quality of life in cancer patients--an hypothesis.

Authors:  K C Calman
Journal:  J Med Ethics       Date:  1984-09       Impact factor: 2.903

7.  Evaluation of current clinical trial methodology in analgesimetry based on experts' opinions and analysis of several analgesic studies.

Authors:  K Sriwatanakul; L Lasagna; C Cox
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

8.  Evaluating quality-of-life in oncology patients: pilot observations.

Authors:  C A Presant; C Klahr; L Hogan
Journal:  Oncol Nurs Forum       Date:  1981       Impact factor: 2.172

9.  Measuring the meaning of life for patients with incurable cancer: the life evaluation questionnaire (LEQ).

Authors:  P Salmon; F Manzi; R M Valori
Journal:  Eur J Cancer       Date:  1996-05       Impact factor: 9.162

Review 10.  Development of a comprehensive quality of life measurement tool: CARES.

Authors:  C A Schag; R L Heinrich
Journal:  Oncology (Williston Park)       Date:  1990-05       Impact factor: 2.990

View more
  3 in total

Review 1.  Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review.

Authors:  Ashley Leak; Deborah K Mayer; Sophia Smith
Journal:  Leuk Lymphoma       Date:  2011-05-03

2.  Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors.

Authors:  Juhee Cho; Danbee Kang; Im Ryung Kim; Won Seog Kim; Betty Ferrell; Seok Jin Kim
Journal:  Cancer Res Treat       Date:  2017-03-30       Impact factor: 4.679

3.  Quality of Life of Cancer Patients Treated with Chemotherapy.

Authors:  Anna Lewandowska; Grzegorz Rudzki; Tomasz Lewandowski; Michał Próchnicki; Sławomir Rudzki; Barbara Laskowska; Joanna Brudniak
Journal:  Int J Environ Res Public Health       Date:  2020-09-23       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.